US 12,070,443 B2
Methods of treating and preventing breast cancer with S-equol
Rong Li, San Antonio, TX (US); Bin Yuan, San Antonio, TX (US); and Tyler Curiel, San Antonio, TX (US)
Assigned to The Board of Regents of the University of Texas System, Austin, TX (US)
Filed by The Board of Regents of the University of Texas System, Austin, TX (US)
Filed on Jul. 9, 2021, as Appl. No. 17/372,352.
Application 17/372,352 is a continuation of application No. 16/384,417, filed on Apr. 15, 2019, granted, now 11,090,286.
Claims priority of provisional application 62/685,392, filed on Jun. 15, 2018.
Prior Publication US 2021/0338632 A1, Nov. 4, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/353 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01)
CPC A61K 31/353 (2013.01) [A61K 39/3955 (2013.01); A61P 35/00 (2018.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01)] 19 Claims
 
1. A method for treating triple-negative breast cancer, comprising administering to a patient diagnosed with triple-negative breast cancer a composition comprising equol and an anti-PD-1 antibody in a combination which is effective to reduce the size of a triple-negative breast cancer tumor in said patient, wherein said equol consists essentially of S-equol.